GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk

26 February 2024 - Submission supported by positive results of a Phase 3 study showing immune response and tolerability in adults ...

Read more →

Health Canada approves Pfizer's bivalent respiratory syncytial virus vaccine for older adults and infants through maternal immunisation

4 January 2024 - Abrysvo is the only RSV vaccine authorised in Canada for maternal immunisation. ...

Read more →

Pfizer and BioNTech receive Health Canada authorisation for XBB.1.5 adapted monovalent COVID-19 vaccine

28 September 2023 - The updated vaccine is expected to be available in Canada in the coming weeks. ...

Read more →

Health Canada authorises Moderna COVID-19 vaccine targeting the Omicron XBB.1.5 sub-variant

12 September 2023 - Health Canada has authorised the use of the Moderna Spikevax COVID-19 vaccine targeting the Omicron XBB.1.5 ...

Read more →

Health Canada accepts Valneva’s Chikungunya vaccine license application for review

29 August 2023 - Valneva today announced that Health Canada has completed screening validation of the Company’s regulatory application for ...

Read more →

GSK's Arexvy, the first respiratory syncytial virus vaccine for older adults approved in Canada

4 August 2023 - Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine ...

Read more →

Moderna initiates rolling submission to Health Canada for updated COVID-19 vaccine

29 June 2023 - Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines. ...

Read more →

Valneva files for Chikungunya vaccine authorisation with Health Canada

30 May 2023 - Valneva today announces the filing of a regulatory application with Health Canada for marketing approval of ...

Read more →

Pfizer Canada initiates submission to Health Canada for its bivalent respiratory syncytial virus vaccine

14 April 2023 - Indications under review include prevention of respiratory syncytial virus in infants from birth through 6 months ...

Read more →

Health Canada authorises Moderna's Omicron targeting bivalent COVID-19 vaccine in children & adolescents (6-17 years)

17 February 2023 - The recommendation is based on clinical data for Moderna's bivalent Omicron targeting COVID-19 vaccine, mRNA.1273.214. ...

Read more →

Health Canada authorises the Pfizer-BioNTech Omicron BA.4/BA.5 bivalent adapted COVID-19 booster for children 5 to 11 years of age

9 December 2022 - Today, Health Canada authorised the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent adapted booster for use in children 5 ...

Read more →

VBI Vaccines announces Health Canada approval for PreHevbrio for the prevention of hepatitis B in adults

8 December 2022 - VBI Vaccines today announced that Health Canada has approved PreHevbrio [3 antigen hepatitis B vaccine (recombinant)] for ...

Read more →

Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents

7 December 2022 - Novavax today announced that Health Canada has approved a supplement to a new drug submission for Nuvaxovid ...

Read more →

GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review

25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against ...

Read more →

Novavax’s COVID-19 booster has been approved for adults, Health Canada says

17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...

Read more →